



HAL
open science

A missense mutation in the CSTF2 gene that impairs the function of the RNA recognition motif and causes defects in 3' end processing is associated with intellectual disability in humans

Petar N Grozdanov, Elahe Masoumzadeh, Vera M Kalscheuer, Thierry Bienvenu, Pierre Billuart, Marie-Ange Delrue, Michael P Latham, Clinton C Macdonald

► **To cite this version:**

Petar N Grozdanov, Elahe Masoumzadeh, Vera M Kalscheuer, Thierry Bienvenu, Pierre Billuart, et al.. A missense mutation in the CSTF2 gene that impairs the function of the RNA recognition motif and causes defects in 3' end processing is associated with intellectual disability in humans. *Nucleic Acids Research*, 2020, 48 (17), pp.9804-9821. 10.1093/nar/gkaa689 . hal-02969371

HAL Id: hal-02969371

<https://hal.science/hal-02969371>

Submitted on 16 Oct 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A missense mutation in the *CSTF2* gene that impairs the function of the RNA recognition motif and causes defects in 3' end processing is associated with intellectual disability in humans

Petar N. Grozdanov^{1,*}, Elahe Masoumzadeh^{2,†}, Vera M. Kalscheuer³, Thierry Bienvenu⁴, Pierre Billuart⁴, Marie-Ange Delrue⁵, Michael P. Latham^{1b,2,*} and Clinton C. MacDonald^{1b,1,*}

¹Department of Cell Biology & Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430-6540, USA, ²Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, TX 79409-1061, USA, ³Max Planck Institute for Molecular Genetics, Research Group Development and Disease, Ihnestr. 63-73, D-14195 Berlin, Germany, ⁴Institut de Psychiatrie et de Neurosciences de Paris, Inserm U1266, 102 rue de la Santé, 75014 Paris, France and ⁵Département de Génétique Médicale, CHU Sainte Justine, Montréal, Canada

Received January 30, 2020; Revised August 03, 2020; Editorial Decision August 04, 2020; Accepted August 18, 2020

ABSTRACT

***CSTF2* encodes an RNA-binding protein that is essential for mRNA cleavage and polyadenylation (C/P). No disease-associated mutations have been described for this gene. Here, we report a mutation in the RNA recognition motif (RRM) of *CSTF2* that changes an aspartic acid at position 50 to alanine (p.D50A), resulting in intellectual disability in male patients. In mice, this mutation was sufficient to alter polyadenylation sites in over 1300 genes critical for brain development. Using a reporter gene assay, we demonstrated that C/P efficiency of *CSTF2*^{D50A} was lower than wild type. To account for this, we determined that p.D50A changed locations of amino acid side chains altering RNA binding sites in the RRM. The changes modified the electrostatic potential of the RRM leading to a greater affinity for RNA. These results highlight the significance of 3' end mRNA processing in expression of genes important for brain plasticity and neuronal development.**

INTRODUCTION

Learning, memory, and intelligence require synaptic plasticity involving persistent changes in neural gene expression. Abnormalities in brain development can result in neurodevelopmental disorders that impact intellectual functioning, behavioral deficits involving adaptive behaviors and autism spectrum disorders. Most neuronal developmental

changes are accomplished by post-transcriptional processes that alter the regulation and protein coding capacity of specific mRNAs (1,2). Similarly, neurodegenerative conditions are associated with altered mRNA metabolism. Frequently, mRNAs in the brain have extremely long 3' untranslated regions (UTRs), and altered 3' UTRs in *MECP2* (Rett syndrome), *APP* (Alzheimer disease) and *HTT* (Huntington disease) are associated with improper metabolism of each of these mRNAs leading to disease states. Though rarer, monogenic forms of intellectual deficiencies offer specific insight into neuronal plasticity and development. The most common monogenic forms of intellectual deficiency are X-linked (XLID (3,4)). For example, Fragile X Syndrome is caused by expansion of CGG repeats in the 5' UTR of *FMRI*, resulting in loss-of-function of FMRP, an RNA-binding protein that promotes transport of mRNAs to dendrites for protein synthesis at synaptic sites (5,6). Similarly, mutations in mRNA processing genes encoding decapping enzymes (7,8), the polyglutamine binding protein 1 (*PQBPI* (9)), spliceosomal proteins (10), hnRNA-binding proteins (11), mRNA surveillance proteins (12) and cleavage and polyadenylation factors (13,14) cause intellectual disabilities. These disorders are associated with changes in the mRNA processing landscape, especially 3' end cleavage and polyadenylation (C/P), highlighting the importance of RNA processing in controlling neuronal function (15–18).

More than eighty different proteins are involved in mRNA C/P (19). Two core C/P factors are the cleavage and polyadenylation specificity factor (CPSF) and the cleavage stimulation factor (CstF). CPSF has six subunits

*To whom correspondence should be addressed. Tel: +1 806 743 2524; Email: clint.macdonald@ttuhsc.edu
Correspondence may also be addressed to Michael P. Latham. Tel: +1 806 834 2564; Email: michael.latham@ttu.edu
Correspondence may also be addressed to Petar N. Grozdanov. Tel: +1 806 743 4124; Email: petar.grozdanov@ttuhsc.edu

†The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.

that recognize the polyadenylation signal (AAUAAA and closely related sequences), cleaves the nascent pre-mRNA, then recruits the poly(A) polymerase, which adds up to 250 non-template adenosines to the upstream product of the cleavage reaction (20,21). CstF is the regulatory factor in C/P, consisting of three subunits, CstF-50 (gene symbol *CSTF1*), CstF-64 (*CSTF2*) and CstF-77 (*CSTF3*). *CSTF2*, the RNA-binding component of CstF, binds to U- or GU-rich sequences downstream of the cleavage site through its RNA recognition motif (RRM (22)). As such, *CSTF2* regulates gene expression in immune cells (23–25), spermatogenesis (26–29), and embryonic stem cell development (30,31). Furthermore, the *CSTF2* paralog, *Cstf2t* has been shown to affect learning and memory in mice (32).

Here, we describe members of a family in whom a single nucleotide mutation in the RRM of *CSTF2* changes an aspartic acid at amino acid 50 to an alanine (D50A). The probands presented with non-syndromic intellectual disability. The mutation, which is X-linked, co-segregated with the clinical phenotype. In a reporter gene assay, *CSTF2* containing the D50A mutation (*CSTF2^{D50A}*) reduced C/P by 15%. However, the *CSTF2^{D50A}* RRM showed an almost 2-fold increase in its affinity for RNA. Solution state nuclear magnetic resonance (NMR) studies showed that the overall backbone structure of the *CSTF2^{D50A}* RRM was similar to wild type. However, repositioning of side chains in RNA binding sites and the α 4-helix resulted in changes in the electrostatic potential and fast timescale protein dynamics of the RNA-bound state. Together, these changes led to an increased affinity of the *CSTF2^{D50A}* RRM for RNA due to a faster k_{on} rate. Differential gene expression analysis of RNA isolated from brains of male mice harboring the D50A mutation (*Cstf2^{D50A}*) identified fourteen genes important for synapse formation and neuronal development. Genome-wide 3' end sequencing of polyadenylated mRNAs identified >1300 genes with altered C/P sites, leading to alternative polyadenylation of genes involved in neurogenesis, neuronal differentiation and development, and neuronal projection development. Our results indicate that in affected individuals, different affinity and rate of binding to the nascent mRNAs of the mutant *CSTF2* RRM could misregulate expression of genes critical for brain plasticity and development.

MATERIALS AND METHODS

Human subjects

All cases had a normal karyotype, were negative for FMR1 repeat expansion, and large insertions or deletions were excluded using array Comparative Genomic Hybridization (CGH). The study was approved by all institutional review boards of the participating institutions collecting the samples, and written informed consent was obtained from all participants or their legal guardians.

DNA isolation and X-chromosome exome sequencing and segregation analysis

DNAs from the family members were isolated from peripheral blood using standard techniques. X-chromosome

exome enrichment using DNA from the index patient, sequencing and analysis was performed as previously described (4). Segregation analysis of variants of uncertain clinical significance was performed by PCR using gene-specific primers flanking the respective variant identified followed by Sanger sequencing.

Animal use and generation of *Cstf2^{D50A}* mice

All animal treatments and tissues obtained in the study were performed according to protocols approved by the Institutional Animal Care and Use Committee at the Texas Tech University Health Sciences Center in accordance with the National Institutes of Health animal welfare guidelines. TTUHSC's vivarium is AAALAC-certified and has a 12-/12-h light/dark cycle with temperature and relative humidity of 20–22°C and 30–50%, respectively.

B6;*Cstf2^{em1Cema-D50A}* founder mice (herein *Cstf2^{D50A}*; hemizygous males are designated *Cstf2^{D50A/Y}*) were generated by Cyagen US Inc. (Santa Clara, CA, USA). To create C57BL/6 mice with a point mutation (D50A) in the *Cstf2* locus, exon 3 in the mouse *Cstf2* gene (GenBank accession number: NM_133196.6; Ensembl: ENSMUSG00000031256) located on mouse chromosome X was selected as the target site. The D50A (GAT to GCT, see Figure 1 and Supplementary Figure S1) mutation site in the donor oligo was introduced into exon 3 by homology-directed repair. A gRNA targeting vector and donor oligo (with targeting sequence, flanked by 120 bp homologous sequences combined on both sides) was designed. *Cas9* mRNA, sgRNA and donor oligo were co-injected into zygotes for knock-in mouse production. The pups were genotyped by PCR followed by sequence analysis. Positive founders were bred to the next generation (F1) and subsequently genotyped by PCR and DNA sequencing analysis. Mutants were maintained as a congenic strain by backcrossing four generations to C57BL/6Ncrl (Charles River) and subsequently breeding exclusively within the colony. At the time of this study, mice were bred to ~10 generations.

Genotyping of *Cstf2^{D50A}* mice by PCR and restriction enzyme digestion

Genomic DNA was extracted from tail snips of *Cstf2^{D50A}* mice by proteinase K digestion followed by isopropanol precipitation (26). PCRs were performed using specific primers surrounding the D50A mutation site. The presence of the mutation converted a CGATAGG sequences to CGCTAGG, thus introducing a *BfaI* restriction site (underlined). Digestion of the PCR products with *BfaI* revealed the presence of the mutation (Supplementary Figure S1, PCR-RFLP). Forward primer: 5'-GAAAGCAGTCAGAGTGGGCT-3'; reverse primer: 5'-CTGCGAAGGAAAGTGAGGGT-3'.

Cell culture, transfection, stem-loop assay for polyadenylation, immunohistochemistry, tissue protein isolation and western blots

Culturing of HeLa cells was performed as described (22). Transfection was carried out in a 24-well plates using Lipofectamine LTX (ThermoFisher Scientific) and 250 ng of a




Figure 1. Family P167 carries a mutation in the X-linked *CSTF2* gene that affects intelligence in males. (A) Pedigree of family 167 showing the index proband (III:1) who was 6 years old at the time of the study, his affected brother (III:2), and two affected uncles (II:1 and II:2). Females (I:2 and II:4) were carriers for the trait, consistent with an X-linked recessive trait. Individuals labeled Mut (II:1, II:2, III:1, III:2) or Mut/WT (II:4) were tested for co-segregation of the mutation with the clinical phenotype by PCR and Sanger sequencing of the specific products. (B) The missense mutation in exon 3 of *CSTF2* substitutes an alanine codon for an aspartic acid at position 50 (p.D50A) within the RNA recognition motif (RRM). (C) CLUSTAL alignment of *CSTF2* orthologs in twenty-eight species indicate that the aspartic acid (amino acid D) at position 50 (red arrow) is highly conserved. Amino acids comprising site-I (Y25 and R85) and site-II (N19 and N91) are indicated in green and blue, respectively. An “*” (asterisk) indicates amino acids that are conserved; a “:” (colon) indicates amino acids with a score greater than 0.5 in the Clustal Omega matrix; and a “.” (period) indicates amino acids with a score smaller or equal to 0.5 in the Clustal Omega matrix. (D) Domains of human *CSTF2* (577 amino acids). Indicated are the RRM, the Hinge, the proline/glycine-rich region, the 12× MEARA repeats, and the C-terminal domain. Numbers at top indicate the amino acid positions of interest.

mixture of plasmid DNAs. Luciferase measurements were performed between 36 and 48 h after the transfection (22,33,34). Western blots to assess the abundance of the proteins were performed on the same volumes of lysates obtained from the luciferase measurements using the passive lysis buffer supplied with the Dual-Luciferase Reporter Assay System (Promega). Antibodies used for western blots were previously described (22,35). Immunohistochemistry and microscopic imaging were performed as described (22).

Protein tissue samples (wild type and *Cstf2^{D50A/Y}*) were obtained from four brothers from the same litter. The entire brain and pieces representing all lobes of the liver were collected from the animals and homogenized in 3 ml RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxycholate) supplemented with PMSF and Halt™ Protease Inhibitor Cocktail (ThermoFischer). Samples were homogenized with several strokes of Brinkmann polytron homogenizer and a third of the volume was spun at $16\,000 \times g$ for 10 min at 4°C. The supernatant was frozen at -80°C until use. 20 µg total protein from the brain and the liver was separated using 8% SDS-PAGE, then transferred to an Immobilon-P PVDF membrane, 0.45 µm (Sigma-Aldrich). Membranes were incubated overnight at 4°C with mouse anti-CSTF2 antibody clone 3A7 (35), rabbit anti-CSTF3 antibody (Bethyl laboratories) and the mouse anti-β-tubulin clone E7 (Developmental Studies Hybridoma Bank, University of Iowa). After the addition of appropriate HRP-conjugated secondary antibody, the immunoreactivity was developed by SuperSignal West Pico Chemiluminescent Substrate (ThermoFischer) and the signal captured using an ImageQuant™ LAS 4000 imager. Images were adjusted for brightness and cropped using ImageJ software.

Plasmids and site-directed mutagenesis

The pGL3 plasmid (Promega), Renilla-luciferase construct (SL-Luc) containing a modified C/P site by the addition of two MS2 stem-loop downstream sequences was previously described (33,36). The D50A mutant was created through site-directed mutagenesis. The RRM (amino acids 1–107) and D50A mutant RRM were cloned in bacterial expression vectors as fusions with a His-tag followed by a TEV site at the amino terminal end of the RRM and was previously described (22). All plasmids were verified by sequencing before use.

Bacterial protein expression and purification

Expression and purification of the proteins over metal affinity resin and His-tag removal was as done before (22). For the NMR experiments, transfected Rosetta (DE3) pLysS cells were grown in $2 \times$ minimal M9 media using $^{15}\text{NH}_4\text{Cl}$ (1 g/l) and unlabeled or uniformly ^{13}C -labeled D-glucose (3 g/l) as sole nitrogen and carbon sources, respectively (37). Induction of the transfected cells with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG), harvest and purification of the labeled proteins was also carried out as previously described (22).

Circular dichroism and stability assays

Circular dichroism experiments were performed on a JASCO J-815 instrument in 10 mM sodium phosphate, pH 7.25 with 10 µM of either wild type or D50A RRM protein. The spectra were scanned from 185 to 260 nm with 0.1 nm resolution. The average spectrum was obtained from three technical replicates.

Guanidine-HCl experiments were performed in 5 mM HEPES pH 7.4, 50 mM NaCl with 5 µM protein samples. Guanidine-HCl concentrations ranged from 0.5 to 3 M. Protein samples without guanidine-HCl were used as reference. Spectra were collected between 205 and 230 nm with 0.1 nm resolution. Values for 216 nm and 222 nm were plotted to represent the denaturation of the secondary structure of the proteins for β-sheets and α-helices, respectively. The average spectra were obtained from three technical replicates.

3'-End fluorescent RNA labeling and fluorescence polarization/anisotropy

SVL (5'-AUUUUAUGUUUCAGGU-3') and (GU)₈ (5'-GUGUGUGUGUGUGUGUGU-3') RNAs were commercially synthesized (Sigma-Aldrich). 3'-end fluorescent labeling of the RNAs with fluorescein-5-thiosemicarbazide (ThermoFisher) was done as previously reported (38). The labeled RNAs were used as 3.2 nM final concentration in polarization assays.

Fluorescence polarization experiments were performed in binding buffer (16 mM HEPES pH 7.4, 40 mM NaCl, 0.008% (vol/vol) IGEPAL CA630, 5 µg/ml heparin, and 8 µg/ml yeast tRNA). Purified wild type and D50A RRM were diluted in 20 mM HEPES pH 7.4, 50 mM NaCl, 0.01% NaN₃ and 0.0001% IGEPAL CA630 to 32 µM concentration and used for 2-fold serial dilutions. The highest final concentration of the protein in the polarization assay was 16 µM. Fluorescence polarization samples were equilibrated for 2 h at room temperature in 96-well black plates (Greiner Bio) and measured on Infinite M1000 PRO instrument (Tecan Inc) with excitation set at 470 nm (5 nm bandwidth) and emission 520 nm (5 nm bandwidth). At least three technical replicates were performed. The apparent dissociation constants were calculated by fitting the data to a modified version of the Hill equation (39) using GraphPad Prism version 5.2 software for Windows (GraphPad Software). Unpaired *t*-test was performed using Microsoft Excel (Microsoft Corp).

Isothermal titration calorimetry (ITC)

The RRM wild type, D50A mutant RRM proteins with SVL RNA were dialyzed overnight into 10 mM sodium phosphate, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 0.05% (v/v) sodium azide, pH 6 using a 2 kDa MWCO dialysis unit (ThermoFisher). Heats of binding were measured using a MicroCal iTC200 calorimeter (GE Healthcare) with a stirring rate of 1000 rpm at 27°C. For all titrations, isotherms were corrected by subtracting the heats of RNA dilution. The concentrations of proteins and RNA were calculated by absorbance spectroscopy with extinction coefficients of $\epsilon_{280} = 5960 \text{ M}^{-1} \text{ cm}^{-1}$ and $\epsilon_{260} = 165.7 \text{ M}^{-1}$

cm^{-1} , respectively. Data were analyzed by Origin 7, and all measurements were performed at least three times.

NMR techniques

NMR experiments were recorded in 10 mM phosphate buffer pH 6.0 with 1 mM TCEP, 0.05% (w/v) sodium azide, 0.1 mg/ml 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), and 10% D_2O using an Agilent 600 MHz (14.1 T) DD2 NMR spectrometer equipped with a room temperature HCN z -axis gradient probe. Data were processed with NMRPipe/NMRDraw (40) and analyzed with CCPN Analysis (41). Backbone $^{13}\text{C}\alpha$, $^{13}\text{C}\beta$, $^{13}\text{C}'$, ^{15}N and ^1HN resonance assignments of RRM wild type and D50A mutant, both in the apo and SVL-bound states were obtained from standard gradient-selected, triple-resonance HNCACB, HN(CO)CACB, HNCO, HN(CA)CO (42) and CHH-TOCSY (43) at 27°C. Assignment data were collected with a random nonuniform sampling scheme and processed by Sparse Multidimensional Iterative Lineshape-Enhanced (SMILE) algorithm (44). Amide group residual dipolar couplings (RDCs; $^1\text{D}_{\text{NH}}$) were measured from 2D ^{15}N , ^1H In-Phase/Anti-Phase (IPAP) experiments recorded on wild type and D50A mutant protein samples in the absence ($^1\text{J}_{\text{NH}}$) and presence ($^1\text{J}_{\text{NH}} + ^1\text{D}_{\text{NH}}$) of filamentous Pf1 bacteriophage (45) and bicelles alignment media (46). For samples in Pf1 bacteriophage, a concentrated stock of protein was mixed with 50 mg/ml bacteriophage stock solutions (Asla) to a final concentration of 15 mg/ml. The bicelle samples contained 5% (w/v) total DLPC and CHAPSO with a molar ratio of 4.2:1 in a 50 mM phosphate buffer, pH 6.8, 50 mM KCl, 1 mM TCEP, 0.05% (w/v) sodium azide, 0.1 mg/ml AEBSF and 10% D_2O . Bicelles were prepared by dissolving DLPC and CHAPSO in phosphate buffer and vortexing for 1 min. Lipids were temperature cycled three times (30 min at 4°C followed by 30 min at 40°C), then diluted 1:1 with wild type or D50A RRM. Samples were equilibrated at 27°C for 1 h before recording the NMR spectra. The DLPC/CHAPSO bicelle samples were stable at 27°C for 3 days.

Wild type (BMRB id: 30652) and D50A (BMRB id: 30653) RRM backbone assignments and amide RDC data from Pf1 bacteriophage were submitted to the CS-ROSETTA webserver (<https://csrosetta.bmrwisc.edu/csrosetta/submit>) for structure calculation (47). The 10 lowest energy structures from CS-ROSETTA were fitted to the RDC data collected in DLPC/CHAPSO bicelles with the PALES program (48). The best wild type and D50A mutant structures are available at protein data bank (PDB codes: 6Q2I for wild type and 6TZE for D50A). The surface electrostatic potential for each structure was calculated with the Adaptive Poisson-Boltzmann Solver (APBS), and figures were generated with PyMol (49).

RNA titration experiments were performed by adding unlabeled SVL RNA to the ^{15}N -labeled proteins and monitoring the change in amide chemical shifts in 2D ^{15}N , ^1H HSQC spectra until complete saturation. Binding affinities were calculated from spectra using a two-state ligand binding model in the TITAN program (50). RNA binding on- and off-rates were calculated for both wild type and D50A RRM from amide peaks in the fast and intermediate ex-

change regimes by TITAN. Backbone ^{15}N R_1 (longitudinal spin–lattice relaxation rate), R_2 (transverse spin–spin relaxation rate) and heteronuclear $\{^1\text{H}\}$ - ^{15}N NOE relaxation data (51,52) for RRM wild type and D50A mutant in the absence and presence of SVL RNA were acquired at 600 MHz and 27°C. ^{15}N R_1 , R_2 . NOE values were used to calculate the backbone order parameters (S^2) and the global correlation time (τ_c) from the model-free approach (53,54) using ‘model 2’ in modelfree v4.2 (<http://nysbc.org/departments/nmr/relaxation-and-dynamics-nysbc/software/modelfree/>).

RNA-seq and 3'-seq

Total brain tissues were collected from three wild type and five mutant 50-day-old male animals from the same litter. Brains were immediately treated with TRIzol reagent (ThermoFisher). RNA isolation, Poly(A)⁺ selection, RNA-seq library preparation (NEBNext[®] UltraTM RNA Library Prep Kit) and high-throughput sequencing (pair end 150-nucleotide sequencing, PE150, 20M unstranded reads per sample), data filtering and quality, mapping on the mouse reference genome (mm10) using the STAR aligner (55) and differential gene expression analysis (DESeq2) (56) were performed by Novogene Corporation. Over-Representation Enrichment Analysis of the differentially expressed genes were assessed using WebGestalt (57) with settings: *Mus musculus*; Overrepresentation Enrichment Analysis; Geneontology; Biological Process. Reference Gene List was set on genome. Cellular Component and Molecular Function did not return any gene ontology terms with a false discovery rate (FDR) smaller than or equal to 0.05.

3' End sequencing and library preparation were performed by Admera Health Inc. 3'-seq libraries were prepared using the QuantSeq 3' mRNA-Seq Library Prep Kit REV for Illumina from Lexogen. Libraries were sequenced with a specific sequencing primer as per the manufacturer recommendations. At least 40M stranded reads were obtained per sample. The sequences were aligned using STAR aligner (55). Aligned reads were normalized and the genes changing the C/P sites were identified. Analysis of APA was performed by Admera Health following the protocol and using the latest polyA.DB database developed by the laboratory of Dr. Bin Tian (58). Polyadenylation sites within 24 nt were clustered together to reflect the heterogeneity of the cleavage and polyadenylation process (59). Over Representation Enrichment Analysis of the genes changing C/P sites were assessed using WebGestalt (57) with settings: *Mus musculus*; Overrepresentation Enrichment Analysis; Geneontology; Biological Process. Reference Gene List was set on genome; top 10 gene ontology terms with a false discovery rate (FDR) smaller than or equal to 0.05.

RESULTS

Males in Family P167 presented with mild intellectual disability and a mutation in the RNA recognition motif in *CSTF2*

Family P167 is of Algerian origin currently living in France. The family has four affected male individuals (II:1, II:2, III:1, and III:2, Figure 1) in two different generations con-

nected through the maternal germline. This pattern of inheritance suggested an X-linked trait carried by females I:2 and II:4. The index proband, a 6-year-old boy (III.1) was presented to the Division of Pediatrics at Bicêtre Hospital (Kremlin-Bicêtre, France) with developmental delays. There was no parental consanguinity. He has one affected brother (II.2) and two affected maternal uncles (I.3 and I.4). All affected males were born after uneventful pregnancies and delivery. The index proband (III.1) was born at term with normal weight (3,760 g), height (50 cm) and occipitofrontal circumference (34 cm). Motor milestones, such as walking, were reached within normal limits. Developmental delay was recognized in early childhood during the first years at school and speech development was retarded. Differential scales of intellectual efficiency (Échelles Différentielles d'Efficiency Intellectuelle, EDEI, 60) showed low verbal and nonverbal communication skills, with no other consistent clinical phenotype. He attended a school for children with additional speech therapy and special assistance. Brain MRI showed no specific abnormalities except for an abnormal hypersignal at the posterior thalamic nuclei due to an episode of intracranial hypertension at the age of 9.5 years (data not shown). His two uncles (ages 44- and 46-years-old, II.1 and II.2, Figure 1A) attended a special school for children with learning difficulties. They are both married and employed; one uncle has a 15-year-old unaffected girl, and the other a 7-year-old unaffected girl and a 5-year-old unaffected boy.

Initial karyotype analysis testing for Fragile X and a mutation search in a few selected XLID genes, including *SLC6A8*, *NLGN4* and *JARID1C*, gave normal results. X chromosome exome sequencing of the index proband (III:1) as part of a large study of >500 unrelated males from families with likely XLID (4) identified a 3 bp deletion in *STARD8*, and single nucleotide variants in *ALG13*, *COL4A5* and *CSTF2*. All variants co-segregated with the phenotype: they were present in all affected males and were transmitted through the maternal germline (Figure 1A and data not shown). The single amino acid deletion identified in *STARD8* is present in 180 control males in the Genome Aggregation Database (gnomAD, non-neuro control individuals, <https://gnomad.broadinstitute.org/>) (61,62), and was therefore interpreted as a benign polymorphism. *ALG13* is an established epilepsy-associated gene in females (63), but the *ALG13* missense mutation in Family P167 (chrX:110951509G>A, NCBI RefSeq NM_001099922.3:c.638G>A, p.S213N, rs374748006) has been reported in four control males (gnomAD, non-neuro) and was predicted as a polymorphism or benign variant by MutationTaster2 (64) and the ClinVar database (65). Mutations in *COL4A5* have been associated with X-linked Alport syndrome, also known as hereditary nephritis. The *COL4A5* single nucleotide mutation (chrX:107846262C>A, NM_000495.4:c.2215C>A, NP_203699.1:p.P739H) has not been reported in any publicly available database. However, the same proline residue substituted by an alanine (p.P739A) is most likely a benign polymorphism (44 hemizygous males in gnomAD).

In contrast, the *CSTF2* missense mutation (exon 3, chrX:100077251A>C (GRCh38.p12), RefSeq

NM_001306206.1:c.149A>C) was identified as novel and was not reported in >14 000 control individuals from publicly available databases including gnomAD. The mutation was predicted as disease causing or pathogenic by several prediction tools, including MutationTaster2 (disease causing), DANN (pathogenicity score of 0.9956 with a value of 1 given to the variants predicted to the most damaging (66)) and a high CADD score of 26.9 (67). Furthermore, at the gene level, *CSTF2* is highly constrained with zero known loss-of-function mutations and a Z-score of 3.43 (ratio of observed to expected = 0.37) for missense mutations in gnomAD. Conceptual translation of the cDNA demonstrated a mutation of aspartic acid (GAT) to alanine (GCT) within the RNA recognition motif (RRM) of *CSTF2* (p.D50A, Figure 1B, D). The aspartic acid at position 50 is conserved in every *CSTF2* ortholog surveyed (Figure 1C). We designated this allele *CSTF2*^{D50A}.

Polyadenylation efficiency is reduced by the *CSTF2*^{D50A} mutation

To determine the effectiveness of *CSTF2*^{D50A} in control of C/P, we performed the Stem-Loop Assay for Polyadenylation (SLAP). SLAP permits determination of C/P efficiency of a luciferase reporter gene that contains two MS2 bacteriophage RNA stem-loops in the position of the U/GU-rich region downstream of the SV40 late polyadenylation signal; the stem-loops bind to an MS2 coat protein domain (MCP) engineered at the N-terminus of *CSTF2* in transfected HeLa cells (33). Previously, using this assay we showed that mutations in the RRM of *CSTF2* influenced RNA binding properties of the motif, thus altering reporter gene expression (22). Wild type MCP-*CSTF2* produced a SLAP value of 4.49 ± 0.16 normalized luciferase units (NLU), whereas MCP-*CSTF2*^{D50A} consistently achieved 15% lower polyadenylation efficiency (3.92 ± 0.13 NLU) than wild type MCP-*CSTF2* (Figure 2A).

Mutations in the RNA binding site I and II of *CSTF2* affect the synergetic function of *CSTF2* and *CSTF3* (22). Therefore, we co-expressed *CSTF3* with either MCP-*CSTF2* or MCP-*CSTF2*^{D50A} to determine whether the D50A mutation affects cleavage and polyadenylation in the presence of *CSTF3*. *CSTF3* increased SLAP for both wild type and MCP-*CSTF2*^{D50A} to a similar extent, effectively eliminating the reduction observed in the MCP-*CSTF2*^{D50A} construct expressed alone. Mutations in the *CSTF2* RRM altered nuclear-to-cytoplasmic localization (22). Therefore, we hypothesized that the *CSTF2*^{D50A} mutation might also affect the ratio between nuclear and cytoplasmic *CSTF2*. Immunohistochemical staining revealed that *CSTF2*^{D50A} was localized more in the cytoplasm than wild type *CSTF2* (Figure 2B). Co-expression of *CSTF3* with *CSTF2*^{D50A} increased the nuclear localization of *CSTF2*^{D50A} similar to wild type *CSTF2* protein (Figure 2B and (22)).

The *CSTF2*^{D50A} RRM has a greater affinity for RNA

Because the aspartic acid (D) to alanine (A) mutation changes the charge in the loop connecting the $\beta 2$ and $\beta 3$ -strands (Figures 3 and 4, (22,68)), we wanted




Figure 2. CSTF2^{D50A} is less efficient for C/P because it binds substrate RNA with a higher affinity. (A) SLAP results showing normalized luciferase units (NLU) in HeLa cells without MCP-CSTF2 (–), in cells transfected with MCP-CSTF2 or MCP-CSTF2^{D50A} (black bars) and with CSTF3-Myc (white bars). Western blots to show the expression of FLAG-tagged MCP-CstF-64 (WB: FLAG) or Myc-tagged CSTF3-Myc (WB: Myc). β -tubulin was used as a loading control. Asterisk indicates a statistically significant *P* value equal to 0.0021, by student's t-test with unequal distribution of variance. (B) Immunofluorescent images of the described constructs stained with antibodies against the FLAG tag for MCP-CSTF2 (green), Myc tag for CSTF3 (red), and counterstained with DAPI to delineate the nucleus. (C) The K_d for RNA binding was determined for the isolated RRM domain of wild type CSTF2 and CSTF2^{D50A} mutant via the change in fluorescence polarization of a 3'-end labeled RNA substrate (C, D) and isothermal titration calorimetry (ITC; E, F). Changes in fluorescence polarization for wild type and D50A RRMs binding to SVL (C) and (GU)₈ (D) substrate RNAs. ITC thermograms of wild type (E) and D50A (F) RRM binding to SVL RNA. The K_d and the number of binding sites (*N*) are indicated on the figures along with the corresponding standard deviation from three replicates. Raw injection heats are shown in the upper panels and the corresponding integrated heat changes are shown in the bottom panels versus the molar ratio of RNA to protein. K_d s and thermodynamics, derived from the fits of the ITC data, are provided in Supplementary Table S1.

to determine whether RNA binding was altered in the CSTF2^{D50A} RRM mutant. To measure binding via fluorescence polarization/anisotropy, bacterially expressed CSTF2 and CSTF2^{D50A} RRMs (amino acids 1–107 (22)) were incubated with fluorescently-labeled RNA oligonucleotides from either the SV40 late transcription unit (SVL (69)) or (GU)₈ (68). The wild type RRM bound to the SVL and (GU)₈ RNAs with $K_{d,app}$ of $1.45 \pm 0.07 \mu\text{M}$ and $0.26 \pm 0.02 \mu\text{M}$, respectively (Figure 2C, D and Supplementary Table S1). The CSTF2^{D50A} mutant RRM bound the two RNAs with significantly higher affinities ($K_{d,app}$ $0.93 \pm 0.13 \mu\text{M}$ and $0.17 \pm 0.01 \mu\text{M}$ for the SVL and (GU)₈ RNA, respectively, Figure 2C, D, Supplementary Table S1).

To confirm the RNA-binding affinities, we performed isothermal titration calorimetry (ITC) titrations using the SVL RNA oligonucleotide. The average K_d was $1.52 \pm 0.17 \mu\text{M}$ for wild type RRM and $0.698 \pm 0.06 \mu\text{M}$ for the CSTF2^{D50A} RRM (Figure 2E and F, Supplementary Table S1), which were in the same range as the K_d s measured before. In both cases, binding was driven by a favorable enthalpy overcoming an unfavorable entropy. However, the enthalpy and entropy for mutant and wild type binding to

SVL RNA were different (Figure 2F, Supplementary Table S1). Thus, the enthalpy-entropy compensation for the D50A mutant binding to SVL RNA was greater than that of the wild type RRM, leading to the higher observed affinity, suggesting that CSTF2^{D50A} would bind to RNAs with a greater affinity during C/P.

The D50A mutation affects the side chain interactions and electrostatic surface of the RRM

To characterize the structural and dynamic changes that occur in the CSTF2^{D50A} RRM upon binding to RNA, we turned to solution state nuclear magnetic resonance (NMR) spectroscopy, initially characterizing the general backbone conformation via 2D ¹⁵N,¹H heteronuclear single quantum coherence (HSQC) spectra for the wild type and mutant RRMs. Predictably, the overlay of the HSQC spectra showed differences in the peak positions of the residues in the loop where the D50A mutation is located (Figure 3A and C, green bars). Otherwise, the majority of the residues in the CSTF2^{D50A} RRM showed almost identical NMR spectra as the wild type.




Figure 3. The p.D50A mutation perturbs the environment of the β -sheet and C-terminal α -helix. The 2D ^{15}N , ^1H HSQC of apo (A) RRM WT (green) and RRM D50A (red) and RNA-bound (B) RRM WT•SVL (black) and RRM D50A•SVL (yellow) complexes. All structures were determined from amino acids 1–107 of human CSTF2 or CSTF2^{D50A}. Data were collected at 600 MHz and 27°C. (C) Bar graph indicating backbone amide chemical shift perturbations (CSP) for the RNA-free (Apo) WT and D50A RRM (green) and SVL RNA-bound WT and D50A mutant RRM (red). The CSPs are calculated from the HSQC spectra from panels A and B. (D) The tertiary folds of the wild type CSTF2 and CSTF2^{D50A} RRM domain are similar. Superimposition of the lowest energy solution structure of the WT and D50A RRM in the apo form, after PALES re-scoring against an independent set of RDC data, showing a view of site I (left panel) and the D50A loop (right view). β -strands and α -helices are labelled on the structures; the black arrows indicate the position of residue D50.

Next, we determined the three-dimensional structures of the CSTF2 and CSTF2^{D50A} RRM using CS-Rosetta (47,70). The CSTF2^{D50A} RRM was almost identical to the CSTF2 RRM structure (Figure 3D; 3.081 Å all atom root-mean-square deviation, RMSD), consistent with circular dichroism data (Supplementary Figure S2A). The major difference between the RRM was observed in the α 4-helix, which angled away to make room for the repositioned side chains of the β 4-strand to interact with the α 4-helix. A small difference was also noted in the relative twist of the β -sheet, which includes RNA binding sites-II and -III.

These differences in secondary structural elements resulted from repositioning of the side chains for the residues in the loop surrounding the D50A mutation and in the amino acids involved in site-I (Tyr25 and Arg85) and -II (Phe19 and Asn91; Figures 1C and 4A–C), which are two of the three sites identified as important for RNA interactions in *Rna15*, the yeast homolog of *CSTF2* (71). Specifically, in wild type CSTF2, the carboxylic acid side chain of Asp50 formed a hydrogen bond with the hydroxyl side chain of Thr53 (Figure 4A, left). Replacing the hydrogen bond acceptor with a methyl group disrupted this interaction in CSTF2^{D50A} (Figure 4A, right). In addition, the Arg51 side chain formed a new ion pair interaction with the side chain carbonyl group of Glu52, instead of the backbone carbonyl of the terminal helix α 4 residue Ser103, leading to re-orientation of helix α 4 (Figures 3D and 4A). In the CSTF2^{D50A} RRM, the β 1-strand had a different twist, which allows the aromatic ring of Phe19 (site-II, Figure 1C) to lift up towards the RNA binding pocket (Figure 4B), contributing to the reorientation of helix α 4 in the mutant as the edge of the Phe19 aromatic ring now packs against the aliphatic portions of Asn97, Glu100, and Leu104 of helix α 4. In binding site-I of the wild type RRM, the Tyr25 aromatic ring was adjacent to the amino side chain on Lys55, forming a π -cation interaction (Figure 4C). However, in CSTF2^{D50A}, the Tyr25 ring moved away, allowing Glu26 to form a hydrogen bond with Arg85 (site-I residue), increasing the rigidity in binding site-I (Figure 4C, right). Thus, local differences in side chain arrangement, particularly in binding sites-I and -II, contribute to the differences we observed in RNA binding.

We calculated the electrostatic potentials using the Adaptive Poisson–Boltzmann Solver (72). Changing the negatively charged Asp50 to the non-charged Ala altered the charge distribution of the loop from negative to positive in the mutant (Figure 4D). Binding site-I (Site I, Figure 4D), which forms upon RNA binding (71) in the wild type, was within a cavity with low positive electrostatic potential for RNA binding (Figure 4D, left). However, in the D50A mutant, the hydrogen bonding between Arg85 and Glu26 (Figure 4C and D) moved the positively charged side chain of Arg85 toward the inside of cavity, resulting in a higher positive electrostatic potential distribution in the binding site-I (Figure 4D, right). We hypothesize that this larger positive electrostatic potential could be the driving force for the more favorable enthalpy of binding and the tighter RNA binding affinity.

The D50A mutation affects the structure and dynamics of the RNA-bound RRM

To test effects of RNA binding, the CSTF2 and CSTF2^{D50A} RRM were titrated with SVL RNA to saturation (molar ratio of 2.3:1, RNA to protein) with changes monitored in 2D ¹⁵N, ¹H HSQC spectra (Figures 3B and 5A). Both proteins showed the same binding patterns (i.e. direction, magnitude and exchange regime) for most residues (e.g. Val18, Val20, Ala27, Asp90 and Leu47; Figure 5A). Gly54 located within the D50 loop was perturbed upon addition of RNA to the CSTF2^{D50A} RRM but not the wild type RRM (Figure 5A, left), indicating a potentially new interaction in the mutated domain. Next, we calculated amide chemical shift perturbations (CSPs) between SVL-bound CSTF2 and CSTF2^{D50A} RRM (Figure 3C, red bars). The largest differences were observed in the loop containing the mutation, similar to unbound RRM (Figure 3C, green bars), and other significant amide CSPs (i.e. above the mean, 0.032 ppm for apo and 0.048 ppm for RNA-bound) were observed in the RNA-bound domain for the N-terminus (residues 5–7) near binding site-I (25 and 85), site-II (residues 19 and 91; Figures 1C and 3C), and in the β 2-strand preceding the mutation (Figure 3B and C, red bars).

The on- and off-rates of RNA binding were determined with a simple two state ligand binding model using the 2D NMR line shape analysis program (TITAN, Supplementary Figure S3 (50)). From the RNA-induced perturbations that were in the fast and intermediate exchange regimes, we calculated a K_d of $0.70 \pm 0.02 \mu\text{M}$ for wild type and $0.54 \pm 0.02 \mu\text{M}$ for CSTF2^{D50A}, which followed the trend established by fluorescence polarization and ITC (Supplementary Table S1). The off-rates (k_{off}) were similar for wild type ($305.5 \pm 1.4 \text{ s}^{-1}$) and CSTF2^{D50A} ($312.4 \pm 2 \text{ s}^{-1}$) RRM. Both on-rates were the same as or exceeded the rate of diffusion, a feature seen in other protein-nucleic acid complexes where electrostatic attraction accelerates the on-rate (73,74). However, the on-rate (k_{on}) for CSTF2^{D50A} ($5.83 \pm 0.21 \times 10^8 \text{ M}^{-1} \text{ s}^{-1}$) was faster than the rate for wild type ($4.35 \pm 0.12 \times 10^8 \text{ M}^{-1} \text{ s}^{-1}$). We conclude, therefore, that the lower K_d for CSTF2^{D50A} was primarily due to the faster on-rate for RNA binding to CSTF2^{D50A} compared to the wild type.

We measured ¹⁵N R_1 , R_2 , and nuclear Overhauser effect (NOE) relaxation values at 600 MHz 27°C to derive backbone model-free order parameters (S^2), which report on the amplitude of fast timescale motion and the global correlation time (τ_c) (53,54). In the absence of RNA, the S^2 values for the CSTF2^{D50A} RRM domain differed from wild type only in the D50A loop, which became more rigid (Figure 5B and Supplementary Figure S4A). However, for the RNA-bound structures, the S^2 values indicated different amide group flexibilities in the mutant RRM (Figure 5C and Supplementary Figure S4B). SVL RNA binding to the CSTF2 RRM reduced S^2 values throughout the β -sheet (e.g. residues 18–22 and 44–48), indicating increased flexibility upon RNA binding, in agreement with earlier studies (68,75). However, SVL RNA binding to the CSTF2^{D50A} RRM increased S^2 values for the β -sheet and the α 3-helix adjacent to site-II (Phe19 and Asn91, Figure 5C). This indicated greater rigidity in the pico-to-nanosecond time scale




Figure 4. The altered side chain interactions of CSTF2^{D50A} lead to different local electrostatic surface potentials. Panels A–C show the different side chain orientations and interactions present in the wild type CSTF2 RRM (green) and mutant CSTF^{D50A} RRM (red). (D) Calculated electrostatic potential for wild type (left) and D50A mutant (right) RRM. The red-to-blue surface representation highlights negative-to-positive electrostatic potential from -2 to 2 $k_b T/e$, where k_b is Boltzmann's constant, T is the temperature in Kelvin and e is the charge of an electron.




Figure 5. The p.D50A mutation affects the RNA-binding kinetics and dynamics of the RRM. (A) Overlays of the 2D ^{15}N , ^1H HSQC spectra for the titration of CSTF2 (top panels) and CSTF2^{D50A} (bottom panels) RRM. Red-yellow-blue and red-green-blue gradients represent the 0–100% titration of wild type and D50A RRM with SVL RNA, respectively. Titration data were acquired at 600 MHz and 27°C. All spectra are shown with the same contour base level relative to noise. The magnitude and direction of each titrated residue is shown with arrows and assignment. (B and C) Backbone amide ^{15}N order parameter (S^2) for (B) apo RRM WT (green) and RRM D50A (red) and (C) SVL RNA-bound RRM WT•SVL (black), and D50A•SVL (yellow). The pink lines at an S^2 value of 1.0 denotes the maximum value for the order parameter.

in the RNA binding surface of the D50A mutant when bound to RNA. The order parameter is a measure of conformational entropy within a protein (76,77). Indeed, the wild type RRM, which became more flexible upon RNA binding, pays less of an entropic penalty compared to the D50A mutant (Supplementary Table S1), which maintained the same flexibility upon RNA binding.

We also determined whether the point mutation in D50A changed the stability of the secondary structure of the motif using CD spectroscopy (Supplementary Figure S2B and C). Both RRMs were thermally stable with minimal changes in ellipticity at 100°C (data not shown). However, upon chemical denaturation with guanidine, we observed that the inflection point for the wild type protein was reached at 2 M guanidine and was decreased to at 1.5 M for the CSTF2^{D50A} RRM mutant. This result suggested that secondary structure of the mutant was less stable than the wild type.

The D50A mutation causes differential gene expression in mice

To examine effects of the D50A mutation *in vivo*, we developed *Cstf2*^{D50A} mice using CRISPR-Cas9 technology. Hemizygous male (*Cstf2*^{D50A/Y}) and homozygous female (*Cstf2*^{D50A/D50A}) mice are viable and fertile. Male *Cstf2*^{D50A/Y} mice appear to be runted. To determine CSTF2 protein expression levels in *Cstf2*^{D50A/Y} mice, we isolated total protein from brains and livers of 50-day old wild type and *Cstf2*^{D50A/Y} littermates. *Cstf2*^{D50A/Y} mice expressed slightly higher amounts of CSTF2 in both total brain and liver (Figure 6A). We also noted strong expression of the βCstF-64 splice variant (78,79) in brains of both wild type and *Cstf2*^{D50A/Y} mice (Figure 6A, lanes 1–4, upper band). RNA-seq (see below) did not indicate differential gene expression of the *Cstf2* mRNA in the brains of *Cstf2*^{D50A/Y} mice (Supplementary Table S2), suggesting that protein differences were translational or post-translational.

To further characterize the changes in the brain gene expression, we isolated whole brain RNA from 50-day old male wild type and *Cstf2*^{D50A/Y} littermates and performed RNA-seq. Only fourteen genes showed significant differential mRNA expression between wild type and *Cstf2*^{D50A/Y} male mice; eleven were up-regulated and three were down-regulated (Figure 6B and Supplementary Table S2). Functional gene enrichment analysis for biological processes (57) indicated that up-regulated genes were involved in several brain developmental pathways including hindbrain development, neural tube patterning, head and brain development (Figure 6C), demonstrating that the D50A mutation in *Cstf2* influenced overall expression of key genes in mice. These key genes included *Cbln1* (Figure 6B), which is essential for the formation and maintenance of synaptic integrity and plasticity between granule cells and the Purkinje cells (80).

The D50A mutation affects alternative polyadenylation (APA) of over one thousand genes in mice

To examine specific changes in C/P in the *Cstf2*^{D50A/Y} mice, we performed genome-wide 3' end sequencing (81,82) on

total RNA isolated from brains from 50-day old male wild type and *Cstf2*^{D50A/Y} mice. To simplify the analysis, we focused on (i) genes in which APA changed the length of the last (3'-most) exon which usually contains the 3' UTR and (ii) genes in which APA caused changes in coding regions (CDS, Figure 6D). The site that was farther from the transcription start site of the gene was designated the distal polyadenylation site (dPAS) and the nearer one was designated the proximal polyadenylation site (pPAS) for both types of APA changes. Based on our biochemical and structural analyses showing a higher affinity for RNA associated with the CSTF2^{D50A} RRM and slightly higher protein expression, we hypothesized that on average more genes would be shortened and pPAS would be favored.

In total, 1370 genes changed polyadenylation sites in *Cstf2*^{D50A/Y} mouse brains. Indeed, the number of the genes showing shortening of the last exon in the D50A mice (i.e. favoring the pPAS) was 1.97-fold greater than those showing the opposite pattern (571 versus 290, Figure 6E and Supplementary Table S3). An example of last exon shortening is the RNA Binding Motif Protein 24 (*Rbm24*) gene (Figure 6F). Gene ontology (GO) analysis of the genes shortening the last exon showed localization of macromolecules in cells, retrograde transport, cell migration, and more (Supplementary Table S4). GO terms of the genes lengthening the last exon indicated enrichment in neurogenesis, neuron development, and more (Figure 6G).

The number of genes in which APA caused changes in the CDS favoring the pPAS in *Cstf2*^{D50A/Y} animals was 3.5-fold greater than the number of genes showing the opposite pattern (396 versus 113, Figure 6H and Supplementary Table S5). For example, the mRNA for the shorter version of the Coatmer Protein Complex Subunit Gamma 1 (*Copg1*) gene was increased in *Cstf2*^{D50A/Y} mouse brains (Figure 6I). This isoform was previously reported to be enriched in granule cells of the brain (83). GO term analysis for the 113 genes lengthening their CDSs did not reveal ontologies that were enriched (FDR < 0.05, Supplementary Table S3). However, GO terms for genes with shorter CDSs were enriched for neurogenesis, neurodevelopment and cell adhesion (Figure 6J). We propose that in the patients carrying the D50A mutation, the balance of the critical protein isoforms involved in brain development is disrupted, contributing to their cognitive disability.

We also evaluated the genes involved in the organization and long-term maintenance of the synapses. In addition to up-regulation of the post-synaptic gene *Cbln1* (Figure 6B), our analysis revealed that both the 3' UTR and the CDS of the mRNA encoding the pre-synaptic cell-surface receptor *Nrxn1* is shorter in brains of *Cstf2*^{D50A/Y} mice (Supplementary Figure S5). Similarly, the 3' UTR of *Cntnap2* is longer in mutant mice (Supplementary Figure S5). On the post-synaptic side, 3' UTRs of several genes involved in regulation of protein synthesis, scaffolding and signal transmission (*Shank2*, *Fmr1*, *Cacng4*) were affected by APA (Supplementary Tables S3 and S4).

Finally, we examined hexamer frequencies within 150 nt 5' and 3' of the pPAS and dPAS of sites that are affected in *Cstf2*^{D50A/Y} mice (Supplementary Figure S6). The hex-




Figure 6. Gene expression and 3' APA analyses in brains of *Cstf2^{D50A/Y}* mice. (A) Protein immunoblots of CSTF2/CstF-64 (top), CSTF3/CstF-77 (middle) and β -tubulin (bottom) from two wild type (lanes 1, 2, 5, 6) and two *Cstf2^{D50A/Y}* (3, 4, 7, 8) male mice from indicated tissues (total brain and liver). Bands corresponding to CstF-64, β CstF-64, CstF-77, and β -tubulin are indicated at right. Genotypes of the wild type and *Cstf2^{D50A/Y}* mice were verified by PCR-RFLP as described in the Materials and Methods. (B) Differential gene expression analysis of RNA-seq from total brain samples isolated from 50-day old male wild type and *Cstf2^{D50A/Y}* mice (three wild type and five mutants). Left, volcano plot of the differentially expressed genes. Right, list of genes that are differentially expressed, fold change (\log_2) and adjusted P value ($-\log_{10}$) are indicated. (C) Gene ontology for biological functions of differentially expressed genes in the brains of wild type and *Cstf2^{D50A/Y}* mice. Number (n) on the right indicates the number of genes found in each functional category. (D) Schematic illustration of APA events analyzed. (Top) Genes in which APA changes the length of the last (3'-most) exon. (Bottom) Genes in which APA occurs in the coding region (CDS) changes the protein coding potential of the gene. Proximal polyadenylation site (PAS), distal PAS, start and stop codons in translation, and regions containing cis-acting RNA elements (e.g. miR and RNA-binding protein binding sites) are indicated. (E) Scatter plot showing expression change of proximal PAS isoform (x-axis) and that of the distal PAS isoform (y-axis) in total RNA. Genes with significantly shortened or lengthened 3' ends ($P < 0.05$, Fisher's exact test) in *Cstf2^{D50A/Y}* total mouse brains (three wild type and five mutant) are highlighted in red and blue, respectively. Color coded numbers indicated the number of genes shortened, lengthened, or showing no change. (F) C/P in the last exon of the *Rbm24* gene in wild type (green) or *Cstf2^{D50A/Y}* (rust) mouse brains switch from the distal to the proximal poly(A) sites. Proximal and distal PASs are indicated with the maximum RPM values shown. (G) Top ten gene ontology categories (FDR < 0.05) of enriched biological functions in *Cstf2^{D50A/Y}* mice showing lengthening of their 3'-most exons. Number of genes (n) that are detected in each functional category are shown on the right. (H) Scatter plot showing expression change of proximal PAS isoform (x-axis) and that of distal PAS isoform (y-axis) in total RNA. Genes with significantly shortened or lengthened CDSs ($P < 0.05$, Fisher's exact test) in *Cstf2^{D50A/Y}* or wild type mouse brains are highlighted in red and blue, respectively. Color coded numbers indicated the number of genes shortened, lengthened, or showing no change. (I) C/P in the *Copg1* gene shortens the CDS in *Cstf2^{D50A/Y}* mouse brains (rust) compared to wild type (green). Maximum RPM values are shown for each animal. Gene structure and different transcripts are shown at the bottom. (J) Top ten gene ontology categories (FDR < 0.05) of enriched biological functions in *Cstf2^{D50A/Y}* brains showing shortened transcripts in their CDS. Number of genes (n) that are detected in each functional category are shown on the right.

amer CACACA was most enriched between 50 and 150 nt upstream of the pPAS, while a similar sequence, CAACCA was enriched upstream of dPAS. Downstream sequences tended to be U-rich (pPAS) or A-rich (dPAS).

These changes in 3' UTRs and protein coding capacity of these key synaptic genes in the excitatory synapses may lead to changes in the long-term potentiation, affecting neuronal plasticity and development, consistent with the speech delays and intellectual disability observed in humans.

DISCUSSION

Many monogenic intellectual deficiencies are X-linked (XLIDs) because of hemizyosity of X-chromosomal genes in males (84–86). The X-linked *CSTF2* gene is essential for embryonic growth and development (30,31). Therefore, it was surprising that a single nucleotide mutation in *CSTF2* would result in structural and functional changes in 3' end mRNA processing yet not have lethal effects. Other muta-

tions in the RRM of *CSTF2* have been reported in gnomAD, but with no associated disease (62). As reported here (Figure 1), it appears that the *CSTF2*^{D50A} mutation affects primarily intellectual functions and speech development in the affected males, but effects on other physiological functions were not noted, suggesting that the brain is more sensitive to this particular mutation than other organs. We propose, therefore, that the p.D50A mutation in *CSTF2* results in non-syndromic intellectual deficiency in males by altering RNA binding during C/P, thus changing the expression of key genes in neurodevelopment.

Only one mutation involving a core polyadenylation protein, *NUDT21* (which encodes the 25 kDa subunit of mammalian cleavage factor I), has been implicated in neuropsychiatric disorders resulting in Rett syndrome-like symptoms and intellectual disability (13,14). We did not observe altered expression of *Mecp2* — which is frequently associated with Rett syndrome — in our mouse model (not shown), but observed altered sites of polyadenylation in many other neurodevelopmental genes (Figure 6).

RNA-contact residues in the *CSTF2* RRM play specific roles during C/P (22). Introduction of the D50A mutation into *CSTF2* resulted in a small but consistent reduction in C/P efficiency (Figure 2A). Such a reduction in activity would likely result in altered C/P *in vivo*, favoring proximal sites over more distal sites (87,88). Analysis of genome-wide polyadenylation changes in the *Cstf2*^{D50A/Y} mice indicated exactly that shorter RNAs (3' most exons and changes in the last exon) were enriched in brains of *Cstf2*^{D50A/Y} mice (Figure 6E, H). Residues within the *CSTF2* RRM are also important for functional interactions between *CSTF2* and *CSTF3* during C/P (22). However, we did not observe a reduction in the ratio between MCP-*CSTF2*^{D50A} alone and MCP-*CSTF2*^{D50A} co-expressed with *CSTF3*, which we previously observed with *CSTF2* RRM binding site-I and -II mutants (Figure 2). This suggests that the D50A mutation causes the phenotype independent of the interactions with *CSTF3*. Furthermore, the small decrease in the polyadenylation efficiency in our reporter system might suggest that the mutated protein is retained longer in the cytoplasm (Figure 2B), possibly through increased interaction with cytoplasmic RNAs (22). Indeed, we observed increased levels of *CSTF2* protein (Figure 6A) in the brains of *Cstf2*^{D50A/Y} mice, which could favor proximal sites of C/P. However, we observed no change of *CSTF3* protein in the same samples (Figure 6A). This suggests that the functional level of *CSTF* is unchanged in nuclei of neuronal and hepatic cells (22).

With reduced C/P efficiency, we observed an increased affinity of the *CSTF2*^{D50A} RRM for RNA (Figures 3 and 5), probably also contributing to the retention of *CSTF2*^{D50A} in the cytoplasm (Figure 2B). The K_d of the *CSTF2*^{D50A} RRM for RNA was less than half that of wild type *CSTF2* due to the faster k_{on} rate (Supplementary Table S1). Based on the on- and off-rates, the D50A mutant binds to RNA faster than wild type but releases the RNA with the same off-rate. It has been previously shown that the β_2 - β_3 loop (D50A loop here) is important for the shape recognition of RNA in some RRM containing proteins (89,90). Our structures for the *CSTF2* and *CSTF2*^{D50A} RRMs allowed us to model the differences in RNA binding based on the relative orientation of the side chains of the mutant RRM, electrostatic

potential, and rigidity of individual backbone atoms of the β -sheet, causing faster RNA binding in the mutant (Figure 4D) by helping to overcome the greater entropic penalty of binding resulting from the enhanced rigidity of the β -sheet in the mutant.

This mutation increases the affinity of *CSTF2*^{D50A} for RNA (Figure 2C, D), which we might consider a 'gain-of-function' mutation at the molecular level. However, the mutation leads to reduced polyadenylation efficiency (Figure 2A), which could be considered a loss-of-function. The phenotype observed is intellectual disability (Figure 1), which many would consider to be a loss-of-function. Thus, the mutation appears to be a molecular gain-of-function that causes a loss-of-function phenotype.

To confirm that the *CSTF2*^{D50A} mutation had a neurophysiological effect, we created *Cstf2*^{D50A} mice with the same mutation. Several labs have examined effects of knockdowns of *CSTF2* in cells in culture, but noted altered C/P in only a relatively small number of genes (87,91–93). Unlike those studies, we observed C/P site changes in 1370 genes in the brains of hemizygous *Cstf2*^{D50A/Y} mice (Figure 6). The majority of the changes in our study favored proximal PASs, effectively shortening the CDSs or shortening the length of the last exons (3' UTRs). Why did the knockdown studies have fewer consequences than the D50A point mutation? Possibly, their results were confounded by the presence of τ CstF-64 (gene symbol *CSTF2T*) compensating for decreased *CSTF2* in those cells. In support of that idea, knockout of *Cstf2t* in mice resulted in few phenotypes in most cells (where *Cstf2* was also expressed), but led to severe disruption of spermatogenesis in germ cells (where *Cstf2t* was expressed in the absence of *Cstf2* (26)).

We noted APA in several genes involved in pre-synaptic (*Nrx1* and *Cntnap2*) granule cells and post-synaptic Purkinje cells (*Cbln1*, *Shank2*, *Fmr1* and *Cacng4*) (94). Mutations in these genes have been associated with development disorders, delayed speech, and intellectual disability (6,95–97). It seems possible that these same disruptions are affecting intellectual ability in the human patients.

But it is also possible that cells in the brain (either neurons, glia, or both) are more sensitive to mutations in *CSTF2*. It has long been known that the brain uses alternative polyadenylation extensively to provide transcriptomic diversity and mRNA targeting signals for plasticity and behavioral adaptation (2,98–100). By extending occupancy times on the pre-mRNA, the D50A mutation likely changes the balance of APA to favor shorter mRNAs, thus reducing the effectiveness of over one thousand mRNA transcripts (Figure 6). The brain also expresses a neuron-specific alternatively-spliced isoform of *CSTF2* that contains 49 extra amino acids, called β CstF-64 (Figure 6A, (78,79)). Thus, we speculate that the D50A mutation might interact with the additional domain in β CstF-64 in an as-yet undefined manner to give the brain phenotype.

How does an increase in the affinity of *CSTF2* for RNA result in altered cleavage and polyadenylation? Previous work showed that formation of the C/P complex takes 10–20 seconds for a weak site; assembly on stronger sites is faster (101). We speculate that the increased affinity of *CSTF2*^{D50A} alters the rate of formation of the CstF complex on the downstream sequence element of the nascent

pre-mRNA during transcription (69). We further speculate that the specificity of binding is reduced in CSTF2^{D50A}. This combination of faster binding and reduced specificity could promote increased C/P of weaker sites, which tend to be more proximal (91), not unlike the effects of slower RNA polymerase II elongation (102,103). These C/P changes subsequently affect post-transcriptional regulation of key mRNAs by changing 3' UTR regulation by revealing miRNA or RNA-binding protein sites, or by changing targeted localization of mRNAs to neural projections (16,17,83,104–107). Mutations in *CSTF2* may have even more striking effects in other target tissues. Studying these mutation-induced changes in gene expression will be important for understanding the mechanisms of polyadenylation as well as the intricacies of neuronal development.

DATA AVAILABILITY

High-throughput sequence data has been deposited to the Gene Expression Omnibus (GEO) database repository at NCBI with the accession numbers GSE152976 (RNA-seq) and GSE152975 (3'-seq). The structures of the wild type CSTF2 (PDB 6Q2I) and CSTF2^{D50A} (PDB 6TZE) RRM domains were deposited to the Research Collaboratory for Structural Bioinformatics Protein Data Bank.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

The authors wish to acknowledge R. Bryan Sutton, Michaela Jansen, Kerri A. White, Charles Faust, Anne Rice, Jeffrey Thomas and the members of the Latham laboratory for technical and intellectual contributions. We thank Admera Health for 3'-seq services and Ruijia Wang, Bin Tian and Yun Zhao for assistance with 3'-seq analysis. Microscopy was performed in the Image Analysis Core Facility supported in part by TTUHSC. We thank Helene Maurey (Bicêtre), Florence Pinton (Bicêtre), Brigitte Simon-Bouy (CH Versailles), and Cecile Zordan (Bordeaux), who performed genetic counselling for this family. The authors would also like to thank the Genome Aggregation Database (gnomAD) and the groups who provided exome and genome variant data to this resource. A full list of contributing groups can be found at <https://gnomad.broadinstitute.org/about>.

Author contributions: Conceptualization, V.M.K., P.N.G. and C.C.M.; Methodology, V.M.K., P.N.G., E.M. and M.P.L.; Formal analysis, V.M.K., P.N.G., E.M., T.B., P. B., M.-A.D. and M.P.L.; Writing - Original draft, P.N.G.; Writing - review and editing, V.M.K., P.N.G., E.M., M.P.L. and C.C.M.; Supervision, P.N.G. and C.C.M.

FUNDING

EU FP7 project GENCODYS [241995]; 2017–2018 Presidents' Collaborative Research Initiative of Texas Tech University System, the Department of Cell Biology & Biochem-

istry (Texas Tech University Health Sciences Center); South Plains Foundation; National Institute of General Medical Sciences; NIH [1R35GM128906 to M.P.L.]. Funding for open access charge: Internal funding.

Conflict of interest statement. None declared.

REFERENCES

- Miura,P., Sanfilippo,P., Shenker,S. and Lai,E.C. (2014) Alternative polyadenylation in the nervous system: to what lengths will 3' UTR extensions take us? *Bioessays*, **36**, 766–777.
- Raj,B. and Blencowe,B.J. (2015) Alternative splicing in the mammalian nervous system: Recent insights into mechanisms and functional roles. *Neuron*, **87**, 14–27.
- Jamra,R. (2018) Genetics of autosomal recessive intellectual disability. *Med Genet.*, **30**, 323–327.
- Hu,H., Haas,S.A., Chelly,J., Van Esch,H., Raynaud,M., de Brouwer,A.P., Weinert,S., Froyen,G., Frints,S.G., Laumonnier,F. *et al.* (2016) X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes. *Mol. Psychiatry*, **21**, 133–148.
- Davis,J.K. and Broadie,K. (2017) Multifarious functions of the fragile X mental retardation protein. *Trends Genet.*, **33**, 703–714.
- Mila,M., Alvarez-Mora,M.I., Madrigal,I. and Rodriguez-Revenga,L. (2018) Fragile X syndrome: An overview and update of the FMR1 gene. *Clin. Genet.*, **93**, 197–205.
- Ahmed,I., Buchert,R., Zhou,M., Jiao,X., Mittal,K., Sheikh,T.I., Scheller,U., Vasli,N., Rafiq,M.A., Brohi,M.Q. *et al.* (2015) Mutations in DCPS and EDC3 in autosomal recessive intellectual disability indicate a crucial role for mRNA decapping in neurodevelopment. *Hum. Mol. Genet.*, **24**, 3172–3180.
- Ng,C.K., Shboul,M., Taverniti,V., Bonnard,C., Lee,H., Eskin,A., Nelson,S.F., Al-Raqad,M., Altawalbeh,S., Seraphin,B. *et al.* (2015) Loss of the scavenger mRNA decapping enzyme DCPS causes syndromic intellectual disability with neuromuscular defects. *Hum. Mol. Genet.*, **24**, 3163–3171.
- Kalscheuer,V.M., Freude,K., Musante,L., Jensen,L.R., Yntema,H.G., Gecz,J., Sefiani,A., Hoffmann,K., Moser,B., Haas,S. *et al.* (2003) Mutations in the polyglutamine binding protein 1 gene cause X-linked mental retardation. *Nat. Genet.*, **35**, 313–315.
- Carroll,R., Kumar,R., Shaw,M., Slee,J., Kalscheuer,V.M., Corbett,M.A. and Gecz,J. (2017) Variant in the X-chromosome spliceosomal gene *GPKOW* causes male-lethal microcephaly with intrauterine growth restriction. *Eur. J. Hum. Genet.*, **25**, 1078–1082.
- Bain,J.M., Cho,M.T., Telegrafi,A., Wilson,A., Brooks,S., Botti,C., Gowans,G., Autullo,L.A., Krishnamurthy,V., Willing,M.C. *et al.* (2016) Variants in *HNRNPH2* on the X chromosome are associated with a neurodevelopmental disorder in females. *Am. J. Hum. Genet.*, **99**, 728–734.
- Tarpey,P.S., Raymond,F.L., Nguyen,L.S., Rodriguez,J., Hackett,A., Vandeleur,L., Smith,R., Shoubridge,C., Edkins,S., Stevens,C. *et al.* (2007) Mutations in *UPF3B*, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation. *Nat. Genet.*, **39**, 1127–1133.
- Gennarino,V.A., Alcott,C.E., Chen,C.A., Chaudhury,A., Gillentine,M.A., Rosenfeld,J.A., Parikh,S., Wheless,J.W., Roeder,E.R., Horovitz,D.D. *et al.* (2015) *NUDT21*-spanning CNVs lead to neuropsychiatric disease and altered MeCP2 abundance via alternative polyadenylation. *Elife*, **4**, e10782.
- Alcott,C.E., Yalamanchili,H.K., Ji,P., van der Heijden,M.E., Saltzman,A., Elrod,N., Lin,A., Leng,M., Bhatt,B., Hao,S. *et al.* (2020) Partial loss of CFIm25 causes learning deficits and aberrant neuronal alternative polyadenylation. *Elife*, **9**, e50895.
- Szkop,K.J., Cooke,P.I.C., Humphries,J.A., Kalna,V., Moss,D.S., Schuster,E.F. and Nobeli,I. (2017) Dysregulation of alternative Poly-adenylation as a potential player in autism spectrum disorder. *Front. Mol. Neurosci.*, **10**, 279.
- Fontes,M.M., Guvenek,A., Kawaguchi,R., Zheng,D., Huang,A., Ho,V.M., Chen,P.B., Liu,X., O'Dell,T.J., Coppola,G. *et al.* (2017) Activity-Dependent regulation of alternative cleavage and polyadenylation during hippocampal Long-Term potentiation. *Sci. Rep.*, **7**, 17377.

17. Wanke, K.A., Devanna, P. and Vernes, S.C. (2018) Understanding neurodevelopmental disorders: the promise of regulatory variation in the 3' UTR. *Biol. Psychiatry*, **83**, 548–557.
18. MacDonald, C.C. (2019) Tissue-specific mechanisms of alternative polyadenylation: testis, brain, and beyond (2018 update). *Wiley Interdiscip. Rev. RNA*, **10**, e1526.
19. Shi, Y., Di Giandomartino, D.C., Taylor, D., Sarkeshik, A., Rice, W.J., Yates, J.R. 3rd, Frank, J. and Manley, J.L. (2009) Molecular architecture of the human pre-mRNA 3' processing complex. *Mol. Cell*, **33**, 365–376.
20. Tian, B. and Manley, J.L. (2017) Alternative polyadenylation of mRNA precursors. *Nat. Rev. Mol. Cell Biol.*, **18**, 18–30.
21. Shi, Y. and Manley, J.L. (2015) The end of the message: multiple protein-RNA interactions define the mRNA polyadenylation site. *Genes Dev.*, **29**, 889–897.
22. Grozdanov, P.N., Masoumzadeh, E., Latham, M.P. and MacDonald, C.C. (2018) The structural basis of CstF-77 modulation of cleavage and polyadenylation through stimulation of CstF-64 activity. *Nucleic Acids Res.*, **46**, 12022–12039.
23. Takagaki, Y., Seipelt, R.L., Peterson, M.L. and Manley, J.L. (1996) The polyadenylation factor CstF-64 regulates alternative processing of IgM heavy chain pre-mRNA during B cell differentiation. *Cell*, **87**, 941–952.
24. Edwalds-Gilbert, G. and Milcarek, C. (1995) Regulation of poly(A) site use during mouse B-cell development involves a change in the binding of a general polyadenylation factor in a B-cell stage-specific manner. *Mol. Cell Biol.*, **15**, 6420–6429.
25. Chuvpilo, S., Zimmer, M., Kerstan, A., Glockner, J., Avots, A., Escher, C., Fischer, C., Inashkina, I., Jankevics, E., Berberich-Siebelt, F. *et al.* (1999) Alternative polyadenylation events contribute to the induction of NF-ATc in effector T cells. *Immunity*, **10**, 261–269.
26. Dass, B., Tardif, S., Park, J.Y., Tian, B., Weitlauf, H.M., Hess, R.A., Carnes, K., Griswold, M.D., Small, C.L. and MacDonald, C.C. (2007) Loss of polyadenylation protein τ CstF-64 causes spermatogenic defects and male infertility. *Proc. Natl. Acad. Sci. U.S.A.*, **104**, 20374–20379.
27. Hockert, K.J., Martincic, K., Mendis-Handagama, S.M.L.C., Borghesi, L.A., Milcarek, C., Dass, B. and MacDonald, C.C. (2011) Spermatogenic but not immunological defects in mice lacking the τ CstF-64 polyadenylation protein. *J. Reprod. Immunol.*, **89**, 26–37.
28. Li, W., Yeh, H.J., Shankarling, G.S., Ji, Z., Tian, B. and MacDonald, C.C. (2012) The τ CstF-64 polyadenylation protein controls genome expression in testis. *PLoS One*, **7**, e48373.
29. Grozdanov, P.N., Li, J., Yu, P., Yan, W. and MacDonald, C.C. (2018) *Cstf2t* Regulates expression of histones and histone-like proteins in male germ cells. *Andrology*, **6**, 605–615.
30. Youngblood, B.A., Grozdanov, P.N. and MacDonald, C.C. (2014) CstF-64 supports pluripotency and regulates cell cycle progression in embryonic stem cells through histone 3' end processing. *Nucleic Acids Res.*, **42**, 8330–8342.
31. Youngblood, B.A. and MacDonald, C.C. (2014) CstF-64 is necessary for endoderm differentiation resulting in cardiomyocyte defects. *Stem Cell Res*, **13**, 413–421.
32. Harris, J.C., Martinez, J.M., Grozdanov, P.N., Bergeson, S.E., Grammas, P. and MacDonald, C.C. (2016) The *Cstf2t* polyadenylation gene plays a Sex-Specific role in learning behaviors in mice. *PLoS One*, **11**, e0165976.
33. Hockert, J.A., Yeh, H.J. and MacDonald, C.C. (2010) The hinge domain of the cleavage stimulation factor protein CstF-64 is essential for CstF-77 interaction, nuclear localization, and polyadenylation. *J. Biol. Chem.*, **285**, 695–704.
34. Hockert, J.A. and MacDonald, C.C. (2014) The stem-loop luciferase assay for polyadenylation (SLAP) method for determining CstF-64-dependent polyadenylation activity. *Methods Mol. Biol.*, **1125**, 109–117.
35. Wallace, A.M., Dass, B., Ravnik, S.E., Tonk, V., Jenkins, N.A., Gilbert, D.J., Copeland, N.G. and MacDonald, C.C. (1999) Two distinct forms of the 64,000 Mr protein of the cleavage stimulation factor are expressed in mouse male germ cells. *Proc. Natl. Acad. Sci. U.S.A.*, **96**, 6763–6768.
36. Maciolek, N.L. and McNally, M.T. (2008) Characterization of Rous sarcoma virus polyadenylation site use in vitro. *Virology*, **374**, 468–476.
37. Azatian, S.B., Kaur, N. and Latham, M.P. (2019) Increasing the buffering capacity of minimal media leads to higher protein yield. *J. Biomol. NMR*, **73**, 11–17.
38. Grozdanov, P.N. and Stocco, D.M. (2012) Short RNA molecules with high binding affinity to the KH motif of A-kinase anchoring protein 1 (AKAP1): implications for the regulation of steroidogenesis. *Mol. Endocrinol.*, **26**, 2104–2117.
39. Pagano, J.M., Clingman, C.C. and Ryder, S.P. (2011) Quantitative approaches to monitor protein-nucleic acid interactions using fluorescent probes. *RNA*, **17**, 14–20.
40. Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J. and Bax, A. (1995) NMRPipe: a multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR*, **6**, 277–293.
41. Vranken, W.F., Boucher, W., Stevens, T.J., Fogh, R.H., Pajon, A., Llinas, M., Ulrich, E.L., Markley, J.L., Ionides, J. and Laue, E.D. (2005) The CCPN data model for NMR spectroscopy: development of a software pipeline. *Proteins*, **59**, 687–696.
42. Muhandiram, D.R. and Kay, L.E. (1994) Gradient-Enhanced Triple-Resonance Three-Dimensional NMR experiments with improved sensitivity. *J. Magn. Reson. Ser. B*, **103**, 203–216.
43. Bax, A., Clore, G.M. and Gronenborn, A.M. (1990) ^1H - ^1H correlation via isotropic mixing of ^{13}C magnetization, a new three-dimensional approach for assigning ^1H and ^{13}C spectra of ^{13}C -enriched proteins. *J. Magn. Reson.*, **88**, 425–431.
44. Ying, J., Delaglio, F., Torchia, D.A. and Bax, A. (2017) Sparse multidimensional iterative lineshape-enhanced (SMILE) reconstruction of both non-uniformly sampled and conventional NMR data. *J. Biomol. NMR*, **68**, 101–118.
45. Hansen, M.R., Mueller, L. and Pardi, A. (1998) Tunable alignment of macromolecules by filamentous phase yields dipolar coupling interactions. *Nat. Struct. Biol.*, **5**, 1065–1074.
46. Wang, H., Eberstadt, M., Olejniczak, E.T., Meadows, R.P. and Fesik, S.W. (1998) A liquid crystalline medium for measuring residual dipolar couplings over a wide range of temperatures. *J. Biomol. NMR*, **12**, 443–446.
47. Shen, Y., Lange, O., Delaglio, F., Rossi, P., Aramini, J.M., Liu, G., Eletsky, A., Wu, Y., Singarapu, K.K., Lemak, A. *et al.* (2008) Consistent blind protein structure generation from NMR chemical shift data. *Proc. Natl. Acad. Sci. U.S.A.*, **105**, 4685–4690.
48. Zweckstetter, M. and Bax, A. (2000) Prediction of sterically induced alignment in a dilute liquid crystalline Phase: Aid to protein structure determination by NMR. *J. Am. Chem. Soc.*, **122**, 3791–3792.
49. DeLano, W.L. (2002) PyMOL: an open-source molecular graphics tool. 82–92.
50. Waudby, C.A., Ramos, A., Cabrita, L.D. and Christodoulou, J. (2016) Two-dimensional NMR lineshape analysis. *Sci. Rep.*, **6**, 24826.
51. Kay, L.E., Nicholson, L.K., Delaglio, F., Bax, A. and Torchia, D.A. (1992) Pulse sequences for removal of the effects of cross correlation between dipolar and chemical-shift anisotropy relaxation mechanisms on the measurement of heteronuclear T1 and T2 values in proteins. *J. Magn. Reson.*, **97**, 8972–8979.
52. Kay, L.E., Torchia, D.A. and Bax, A. (1989) Backbone dynamics of proteins as studied by ^{15}N inverse detected heteronuclear NMR spectroscopy: application to staphylococcal nuclease. *Biochemistry*, **28**, 8972–8979.
53. Lipari, G. and Szabo, A. (1982) Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity. *J. Am. Chem. Soc.*, **104**, 4546–4559.
54. Lipari, G. and Szabo, A. (1982) Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 2. Analysis of experimental results. *J. Am. Chem. Soc.*, **104**, 4559–4570.
55. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M. and Gingeras, T.R. (2013) STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*, **29**, 15–21.
56. Love, M.I., Huber, W. and Anders, S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.*, **15**, 550.
57. Liao, Y., Wang, J., Jaehnig, E.J., Shi, Z. and Zhang, B. (2019) WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res.*, **47**, W199–W205.

58. Wang,R., Nambiar,R., Zheng,D. and Tian,B. (2018) PolyA.DB 3 catalogs cleavage and polyadenylation sites identified by deep sequencing in multiple genomes. *Nucleic Acids Res.*, **46**, D315–D319.
59. Tian,B., Hu,J., Zhang,H. and Lutz,C.S. (2005) A large-scale analysis of mRNA polyadenylation of human and mouse genes. *Nucleic Acids Res.*, **33**, 201–212.
60. Fiasse,C. and Nader-Grosbois,N. (2012) Perceived social acceptance, theory of mind and social adjustment in children with intellectual disabilities. *Res. Dev. Disabil.*, **33**, 1871–1880.
61. Lek,M., Karczewski,K.J., Minikel,E.V., Samocha,K.E., Banks,E., Fennell,T., O'Donnell-Luria,A.H., Ware,J.S., Hill,A.J., Cummings,B.B. *et al.* (2016) Analysis of protein-coding genetic variation in 60,706 humans. *Nature*, **536**, 285–291.
62. Karczewski,K.J., Francioli,L.C., Tiao,G., Cummings,B.B., Alfoldi,J., Wang,Q., Collins,R.L., Laricchia,K.M., Ganna,A., Birnbaum,D.P. *et al.* (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*, **581**, 434–443.
63. Bissar-Tadmouri,N., Donahue,W.L., Al-Gazali,L., Nelson,S.F., Bayrak-Toydemir,P. and Kantarci,S. (2014) X chromosome exome sequencing reveals a novel *ALG13* mutation in a nonsyndromic intellectual disability family with multiple affected male siblings. *Am. J. Med. Genet. A*, **164A**, 164–169.
64. Schwarz,J.M., Cooper,D.N., Schuelke,M. and Seelow,D. (2014) MutationTaster2: mutation prediction for the deep-sequencing age. *Nat. Methods*, **11**, 361–362.
65. Landrum,M.J., Lee,J.M., Benson,M., Brown,G., Chao,C., Chitipiralla,S., Gu,B., Hart,J., Hoffman,D., Hoover,J. *et al.* (2016) ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic Acids Res.*, **44**, D862–868.
66. Quang,D., Chen,Y. and Xie,X. (2015) DANN: a deep learning approach for annotating the pathogenicity of genetic variants. *Bioinformatics*, **31**, 761–763.
67. Rentzsch,P., Witten,D., Cooper,G.M., Shendure,J. and Kircher,M. (2019) CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.*, **47**, D886–D894.
68. Deka,P., Rajan,P.K., Perez-Canadillas,J.M. and Varani,G. (2005) Protein and RNA dynamics play key roles in determining the specific recognition of GU-rich polyadenylation regulatory elements by human Cstf-64 protein. *J. Mol. Biol.*, **347**, 719–733.
69. MacDonald,C.C., Wilusz,J. and Shenk,T. (1994) The 64-kilodalton subunit of the CstF polyadenylation factor binds to pre-mRNAs downstream of the cleavage site and influences cleavage site location. *Mol. Cell. Biol.*, **14**, 6647–6654.
70. Ramelot,T.A., Raman,S., Kuzin,A.P., Xiao,R., Ma,L.C., Acton,T.B., Hunt,J.F., Montelione,G.T., Baker,D. and Kennedy,M.A. (2009) Improving NMR protein structure quality by Rosetta refinement: a molecular replacement study. *Proteins*, **75**, 147–167.
71. Pancevac,C., Goldstone,D.C., Ramos,A. and Taylor,I.A. (2010) Structure of the Rna15 RRM-RNA complex reveals the molecular basis of GU specificity in transcriptional 3'-end processing factors. *Nucleic Acids Res.*, **38**, 3119–3132.
72. Baker,N.A., Sept,D., Joseph,S., Holst,M.J. and McCammon,J.A. (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. *Proc. Natl. Acad. Sci. U.S.A.*, **98**, 10037–10041.
73. von Hippel,P.H. and Berg,O.G. (1989) Facilitated target location in biological systems. *J. Biol. Chem.*, **264**, 675–678.
74. Riggs,A.D., Bourgeois,S. and Cohn,M. (1970) The lac repressor-operator interaction. 3. Kinetic studies. *J. Mol. Biol.*, **53**, 401–417.
75. Pérez Cañadillas,J.M. and Varani,G. (2003) Recognition of GU-rich polyadenylation regulatory elements by human CstF-64 protein. *EMBO J.*, **22**, 2821–2830.
76. Yang,D. and Kay,L.E. (1996) Contributions to conformational entropy arising from bond vector fluctuations measured from NMR-derived order parameters: application to protein folding. *J. Mol. Biol.*, **263**, 369–382.
77. Wand,A.J. (2013) The dark energy of proteins comes to light: conformational entropy and its role in protein function revealed by NMR relaxation. *Curr. Opin. Struct. Biol.*, **23**, 75–81.
78. Shankarling,G.S., Coates,P.W., Dass,B. and MacDonald,C.C. (2009) A family of splice variants of CstF-64 expressed in vertebrate nervous systems. *BMC Mol. Biol.*, **10**, 22.
79. Shankarling,G.S. and MacDonald,C.C. (2013) Polyadenylation site-specific differences in the activity of the neuronal β CstF-64 protein in PC-12 cells. *Gene*, **529**, 220–227.
80. Hirai,H., Pang,Z., Bao,D., Miyazaki,T., Li,L., Miura,E., Parris,J., Rong,Y., Watanabe,M., Yuzaki,M. *et al.* (2005) Cbln1 is essential for synaptic integrity and plasticity in the cerebellum. *Nat. Neurosci.*, **8**, 1534–1541.
81. Li,W., Park,J.Y., Zheng,D., Hoque,M., Yehia,G. and Tian,B. (2016) Alternative cleavage and polyadenylation in spermatogenesis connects chromatin regulation with post-transcriptional control. *BMC Biol.*, **14**, 6.
82. Li,W., You,B., Hoque,M., Zheng,D., Luo,W., Ji,Z., Park,J.Y., Gunderson,S.I., Kalsotra,A., Manley,J.L. *et al.* (2015) Systematic profiling of poly(A)+ transcripts modulated by core 3' end processing and splicing factors reveals regulatory rules of alternative cleavage and polyadenylation. *PLoS Genet.*, **11**, e1005166.
83. Jereb,S., Hwang,H.W., Van Otterloo,E., Govek,E.E., Fak,J.J., Yuan,Y., Hatten,M.E. and Darnell,R.B. (2018) Differential 3' processing of specific transcripts expands regulatory and protein diversity across neuronal cell types. *Elife*, **7**, e34042.
84. Penrose,L. (1938) *A Clinical and Genetic Study of 1280 Cases of Mental Defect*. H. M. Stationary Office, London.
85. Raymond,F.L. (2006) X linked mental retardation: a clinical guide. *J. Med. Genet.*, **43**, 193–200.
86. Hu,H., Kahrizi,K., Musante,L., Fattahi,Z., Herwig,R., Hosseini,M., Oppitz,C., Abedini,S.S., Suckow,V., Larti,F. *et al.* (2018) Genetics of intellectual disability in consanguineous families. *Mol. Psychiatry*, **24**, 1027–1039.
87. Yao,C., Biesinger,J., Wan,J., Weng,L., Xing,Y., Xie,X. and Shi,Y. (2012) Transcriptome-wide analyses of CstF64-RNA interactions in global regulation of mRNA alternative polyadenylation. *Proc. Natl. Acad. Sci. U.S.A.*, **109**, 18773–18778.
88. Hwang,H.W., Park,C.Y., Goodarzi,H., Fak,J.J., Mele,A., Moore,M.J., Saito,Y. and Darnell,R.B. (2016) PAPERCLIP identifies MicroRNA targets and a role of CstF64/64tau in promoting non-canonical poly(A) site usage. *Cell Rep.*, **15**, 423–435.
89. Steff,R., Skrisovska,L. and Allain,F.H. (2005) RNA sequence- and shape-dependent recognition by proteins in the ribonucleoprotein particle. *EMBO Rep.*, **6**, 33–38.
90. Skrisovska,L., Bourgeois,C.F., Steff,R., Grellscheid,S.N., Kister,L., Wenter,P., Elliott,D.J., Stevenin,J. and Allain,F.H. (2007) The testis-specific human protein RBMY recognizes RNA through a novel mode of interaction. *EMBO Rep.*, **8**, 372–379.
91. Martin,G., Gruber,A.R., Keller,W. and Zavolan,M. (2012) Genome-wide analysis of pre-mRNA 3' end processing reveals a decisive role of human cleavage factor I in the regulation of 3' UTR length. *Cell Rep.*, **1**, 753–763.
92. Gruber,A.R., Martin,G., Keller,W. and Zavolan,M. (2012) Cleavage factor Im is a key regulator of 3' UTR length. *RNA Biol.*, **9**, 1405–1412.
93. Kim,S., Yamamoto,J., Chen,Y., Aida,M., Wada,T., Handa,H. and Yamaguchi,Y. (2010) Evidence that cleavage factor Im is a heterotetrameric protein complex controlling alternative polyadenylation. *Genes Cells*, **15**, 1003–1013.
94. Yuzaki,M. (2018) Two classes of secreted synaptic organizers in the central nervous system. *Annu. Rev. Physiol.*, **80**, 243–262.
95. Camacho-Garcia,R.J., Planelles,M.I., Margalef,M., Pecero,M.L., Martinez-Leal,R., Aguilera,F., Vilella,E., Martinez-Mir,A. and Scholl,F.G. (2012) Mutations affecting synaptic levels of neuexin-1beta in autism and mental retardation. *Neurobiol. Dis.*, **47**, 135–143.
96. Yangngam,S., Plong-On,O., Sripo,T., Roongpraiwan,R., Hansakunachai,T., Wirojanan,J., Sombuntham,T., Ruangdaraganon,N. and Limprasert,P. (2014) Mutation screening of the neuexin 1 gene in thai patients with intellectual disability and autism spectrum disorder. *Genet Test Mol Biomarkers*, **18**, 510–515.
97. Guang,S., Pang,N., Deng,X., Yang,L., He,F., Wu,L., Chen,C., Yin,F. and Peng,J. (2018) Synaptopathology involved in autism spectrum disorder. *Front Cell Neurosci.*, **12**, 470.
98. Zhang,H., Lee,J.Y. and Tian,B. (2005) Biased alternative polyadenylation in human tissues. *Genome Biol.*, **6**, R100.
99. Miura,P., Shenker,S., Andreu-Agullo,C., Westholm,J.O. and Lai,E.C. (2013) Widespread and extensive lengthening of 3' UTRs in the mammalian brain. *Genome Res.*, **23**, 812–825.

100. Fasken, M.B. and Corbett, A.H. (2016) Links between mRNA splicing, mRNA quality control, and intellectual disability. *RNA Dis*, **3**, e1448.
101. Chao, L.C., Jamil, A., Kim, S.J., Huang, L. and Martinson, H.G. (1999) Assembly of the cleavage and polyadenylation apparatus requires about 10 seconds in vivo and is faster for strong than for weak poly(A) sites. *Mol. Cell. Biol.*, **19**, 5588–5600.
102. Liu, X., Freitas, J., Zheng, D., Oliveira, M.S., Hoque, M., Martins, T., Henriques, T., Tian, B. and Moreira, A. (2017) Transcription elongation rate has a tissue-specific impact on alternative cleavage and polyadenylation in *Drosophila melanogaster*. *RNA*, **23**, 1807–1816.
103. Pinto, P.A., Henriques, T., Freitas, M.O., Martins, T., Domingues, R.G., Wyrzykowska, P.S., Coelho, P.A., Carmo, A.M., Sunkel, C.E., Proudfoot, N.J. *et al.* (2011) RNA polymerase II kinetics in polo polyadenylation signal selection. *EMBO J.*, **30**, 2431–2444.
104. Ciolli Mattioli, C., Rom, A., Franke, V., Imami, K., Arrey, G., Terne, M., Woehler, A., Akalin, A., Ulitsky, I. and Chekulaeva, M. (2019) Alternative 3' UTRs direct localization of functionally diverse protein isoforms in neuronal compartments. *Nucleic Acids Res.*, **47**, 2560–2573.
105. Taliaferro, J.M., Vidaki, M., Oliveira, R., Olson, S., Zhan, L., Saxena, T., Wang, E.T., Graveley, B.R., Gertler, F.B., Swanson, M.S. *et al.* (2016) Distal alternative last exons localize mRNAs to neural projections. *Mol. Cell*, **61**, 821–833.
106. Nazim, M., Masuda, A., Rahman, M.A., Nasrin, F., Takeda, J.I., Ohe, K., Ohkawara, B., Ito, M. and Ohno, K. (2017) Competitive regulation of alternative splicing and alternative polyadenylation by hnRNP H and CstF64 determines acetylcholinesterase isoforms. *Nucleic Acids Res.*, **45**, 1455–1468.
107. Hafner, A.S., Donlin-Asp, P.G., Leitch, B., Herzog, E. and Schuman, E.M. (2019) Local protein synthesis is a ubiquitous feature of neuronal pre- and postsynaptic compartments. *Science*, **364**, eaau3644.